SA
LLY icon

Shilanski & Associates’s Eli Lilly LLY Stock Holding History

Shilanski & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,795
Closed -$2.93M – 108
2024
Q4 		$2.93M Buy
3,795
+21
+0.6% +$17.4K 0.94% 35
2024
Q3 		$3.34M Buy
3,774
+130
+4% +$117K 1.09% 33
2024
Q2 		$3.3M Sell
3,644
-122
-3% -$97.6K 1.11% 31
2024
Q1 		$2.93M Sell
3,766
-161
-4% -$115K 1.01% 32
2023
Q4 		$2.29M Sell
3,927
-8
-0.2% -$4.67K 0.87% 38
2023
Q3 		$2.11M Sell
3,935
-3
-0.1% -$1.55K 0.86% 39
2023
Q2 		$1.85M Buy
3,938
+97
+3% +$40.7K 0.75% 40
2023
Q1 		$1.39M Buy
3,841
+87
+2% +$29.3K 0.63% 41
2022
Q4 		$1.37M Buy
3,754
+2,729
+266% +$968K 0.6% 43
2022
Q3 		$331K Buy
+1,025
New +$325K 0.12% 89

Other funds holding LLY

PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Shilanski & Associates's LLY Position: Q1 2025 in Review

Shilanski & Associates sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 3,795 shares — an estimated $2.93M sold.

Shilanski & Associates first reported a position in LLY in Q3 2022 and held it in 10 quarters. The position peaked at $3.34M in Q3 2024. 3,927 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

  • Shilanski & Associates reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
  • Shilanski & Associates sold 3,795 Eli Lilly shares in Q1 2025, an estimated $2.93M.
  • Shilanski & Associates first reported a position in Eli Lilly in Q3 2022 and held it in 10 quarters.
  • Shilanski & Associates's Eli Lilly position peaked at $3.34M in Q3 2024.
  • 3,927 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on Shilanski & Associates's 13F filing for Q1 2025, filed 25 Apr 2025.